385 results on '"Jachs, Mathias"'
Search Results
2. Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective study
3. ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria
4. Diagnostic and prognostic performance of the LiverRisk score in tertiary care
5. Endoscopic band ligation is safe despite low platelet count and high INR
6. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study
7. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta
8. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure
9. The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation
10. Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)
11. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient
12. Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortality
13. Platelet adhesion assessed by PFA-100 is not linked to progression of ACLD
14. Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease
15. Imaging features facilitate diagnosis of porto-sinusoidal vascular disorder
16. The impact of COVID-19 on liver transplantation programs in Austria
17. Update zum Management der portalen Hypertonie nach Baveno VII – Was ist für die Praxis relevant?
18. Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis
19. An impaired pituitary–adrenal signalling axis in stable cirrhosis is linked to worse prognosis
20. Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression
21. Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis
22. Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis
23. The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension
24. Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis
25. Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
26. Non-selective Beta Blockers in Liver Cirrhosis
27. SAT-080-YI Residual minimal ascites 3 months after TIPS implantation indicates risk of further decompensation and death
28. TOP-097-YI Dynamics of systemic inflammation after TIPS implantation and their impact on acute-on-chronic liver failure and liver-related death
29. FRI-009-YI Diagnostic and prognostic performance of the LiverRisk score in tertiary care
30. OS-096-YI Spleen stiffness measurement by transient elastography at 100 Hz refines the non-invasive diagnosis of clinically significant portal hypertension in compensated advanced chronic liver diseasefinal results of a european multicenter study
31. SAT-105 Neutrophil extracellular traps are not linked to the development of decompensation, ACLF, or death in clinically stable patients with advanced chronic liver disease
32. WED-171 Spleen stiffness and VWF-based non-invasive tests reflect severity of prehepatic and presinusoidal portal hypertension
33. THU-075-YI Incidence and prognostic value of zinc and seleniumdeficiency in cirrhosis
34. SAT-086-YI Assessment of portal hypertension risk by liver and spleen stiffness using real-time 2D-shear wave elastography-the prospective AiXplore study
35. THU-381 Prognostic implications of liver stiffness impairment after HCV cure in cACLD patients
36. SAT-128 Circulating fibronectin levels are linked to endothelial dysfunction, fibrogenesis, and portal hypertension in advanced chronic liver disease
37. WED-391 Long-term virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with bulevirtide monotherapy for up to 120 weeks: a retrospective multicenter european study (save-d)
38. WED-383 Antiviral efficacy of REP 2139-Mg and effects on HVPG in HDV/HBV coinfected patients with cirrhosis and portal hypertension nonresponding to previous bulevirtide treatment
39. SAT-111 Lower levels of Insulin-like growth factor 1 are independently associated with unfavorable prognosis in patients with advanced chronic liver disease
40. OS-120 Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis
41. FRI-394 High burden of cirrhosis and increasing response rates to bulevirtide-based regimens: insights from the austrian prospective hepatitis D registry
42. THU-071 Impact of underlying portal hypertension and systemic inflammation on acute-on-chronic liver failure (ACLF) severity and outcome
43. OS-034 Safety and efficacy of REP 2139-Mg in hepatitis D patients with advanced liver disease: an international compassionate use program
44. Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease
45. Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event
46. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death
47. High histamine levels are associated with acute‐on‐chronic liver failure and liver‐related death in patients with advanced chronic liver disease.
48. Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease.
49. Long‐term outcome of hepatitis delta in different regions world‐wide: Results of the Hepatitis Delta International Network.
50. Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.